ZYLOXTB (02190) announced its interim results, with shareholders' profit attributable to them amounting to 182 million yuan, an increase of 49.93% year-on-year.

ZYLOXTB (02190) announced its interim results for the six months ended June 30, 2026, with revenue of 632 million yuan (RMB, the same below), an increase of 31.1% year-on-year; gross profit of 464 million yuan, an increase of 35.2% year-on-year; profit attributable to shareholders of 182 million yuan, an increase of 49.93% year-on-year; and basic earnings per share of 0.57 yuan. The announcement stated that 57.9% of the company's product revenue came from neurovascular intervention products, and 39.1% from peripheral vascular intervention products. The significant growth in the company's revenue was primarily attributed to the rapid increase in sales of neurovascular and peripheral vascular intervention devices. In the first half of 2026, the sales revenue from neurovascular intervention products increased by 20.2% compared to the first half of 2025, mainly due to (i) the promotion and rapid penetration of relatively newer approved products nationwide, such as the Dragon intracranial aneurysm embolization assist stent, which began generating sales revenue during the reporting period; (ii) stable revenue growth from major mature products like the Qilin blood flow guiding device, Silver Snake intracranial intermediate catheter series, and neurovascular guidewires; and (iii) the company's ongoing commitment to launching products in various international markets. In the first half of 2026, the sales revenue from peripheral vascular intervention products increased by 40.0% compared to the first half of 2025, mainly due to (i) the company's continuous efforts to expand market access, improve hospital penetration rates, and broaden the distribution network, resulting in rapid revenue growth for established products such as the UltraFree drug-eluting PTA balloon dilation catheter (UltraFree DCB), Phoenix peripheral detachable fiber spring coil embolization system, and Swan venous intraluminal radiofrequency closure catheter; (ii) the commercialization of the company's relatively newer product portfolio nationwide, including the Eagle thrombus aspiration system and ZENFLOW Pufferfish peripheral balloon dilatation catheter; and (iii) the acquisition and integration of optimed and the continued commitment to launching products in various international markets.